Ilhan Lim1, Woo Chul Noh2, Inki Lee3, Byung Hyun Byun3, Byung Il Kim3, Chang Woon Choi3, Sang-Keun Woo4, Kwang Il Kim4, Kyo Chul Lee4, Joo Hyun Kang4, Min-Ki Seong5, Hyun-Ah Kim5, Sang Moo Lim3. 1. Department of Nuclear Medicine, Korea Cancer Centre Hospital, Korea Institute of Radiological and Medical Sciences, 75, Nowon-ro, Nowon-gu, Seoul, Korea. ilhan@kcch.re.kr. 2. Department of Surgery, Korea Cancer Centre Hospital, Korea Institutes of Radiological and Medical Sciences, 75, Nowon-ro, Nowon-gu, Seoul, Korea. nohwoo@kirams.re.kr. 3. Department of Nuclear Medicine, Korea Cancer Centre Hospital, Korea Institute of Radiological and Medical Sciences, 75, Nowon-ro, Nowon-gu, Seoul, Korea. 4. Division of Applied RI, Research Institute of Radiological and Medical Sciences, Korea Institutes of Radiological and Medical Sciences, Seoul, Korea. 5. Department of Surgery, Korea Cancer Centre Hospital, Korea Institutes of Radiological and Medical Sciences, 75, Nowon-ro, Nowon-gu, Seoul, Korea.
Abstract
BACKGROUND: The purpose of this study was to evaluate both the biodistribution and safety of 64Cu-1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA)-Trastuzumab, a novel 64Cu-labeled positron emission tomography (PET) tracer for human epidermal growth factor receptor 2 (HER2) in patients with breast cancer. METHODS: PET images at 1, 24, and 48 h after 296 MBq of 64Cu-NOTA-Trastuzumab injection were obtained from seven patients with breast cancer. Both the primary tumors' and metastatic lesions' maximum standardized uptake value (SUVmax) was evaluated. The mean SUVmax (SUVmean) was evaluated in the other organs, including the blood pool, liver, kidney, muscle, spleen, bladder, and the lungs, as well as the bones. Moreover, the internal radiation dosimetry was calculated using the OLINDA/EXM software. Safety was assessed based on feedback regarding adverse reactions and safety-related issues within 1 month after 64Cu-NOTA-Trastuzumab administration. RESULTS: 64Cu-NOTA-Trastuzumab PET images showed that the overall SUVmean values in each organ negatively correlated with time. The liver's average SUVmean values were measured at 5.3 ± 0.7, 4.8 ± 0.6, and 4.4 ± 0.5 on 1 h, 24 h, and 48 h after injection, respectively. The average SUVmean blood values were measured at 13.1 ± 0.9, 9.1 ± 1.2, and 7.1 ± 1.9 on 1 h, 24 h, and 48 h after injection, respectively. The SUVmax of HER2-positive tumors was relatively higher than HER2-negative tumors (8.6 ± 5.1 and 5.2 ± 2.8 on 48 h after injection, respectively). Tumor-to-background ratios were higher in the HER2-positive tumors than in the HER2-negative tumors. No adverse events related to 64Cu-NOTA-Trastuzumab were reported. The calculated effective dose with a 296 MBq injection of 64Cu-NOTA-Trastuzumab was 2.96 mSv. The highest absorbed dose was observed in the liver (0.076 mGy/MBq), followed by the spleen (0.063 mGy/MBq), kidney (0.044 mGy/MBq), and heart wall (0.044 mGy/MBq). CONCLUSIONS: 64Cu-NOTA-Trastuzumab showed a specific uptake at the HER2-expressing tumors, thus making it a feasible and safe monitoring tool of HER2 tumor status in patients with breast cancer. TRIAL REGISTRATION: CRIS, KCT0002790. Registered 02 February 2018, https://cris.nih.go.kr.
BACKGROUND: The purpose of this study was to evaluate both the biodistribution and safety of 64Cu-1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA)-Trastuzumab, a novel 64Cu-labeled positron emission tomography (PET) tracer for humanepidermal growth factor receptor 2 (HER2) in patients with breast cancer. METHODS: PET images at 1, 24, and 48 h after 296 MBq of 64Cu-NOTA-Trastuzumab injection were obtained from seven patients with breast cancer. Both the primary tumors' and metastatic lesions' maximum standardized uptake value (SUVmax) was evaluated. The mean SUVmax (SUVmean) was evaluated in the other organs, including the blood pool, liver, kidney, muscle, spleen, bladder, and the lungs, as well as the bones. Moreover, the internal radiation dosimetry was calculated using the OLINDA/EXM software. Safety was assessed based on feedback regarding adverse reactions and safety-related issues within 1 month after 64Cu-NOTA-Trastuzumab administration. RESULTS:64Cu-NOTA-Trastuzumab PET images showed that the overall SUVmean values in each organ negatively correlated with time. The liver's average SUVmean values were measured at 5.3 ± 0.7, 4.8 ± 0.6, and 4.4 ± 0.5 on 1 h, 24 h, and 48 h after injection, respectively. The average SUVmean blood values were measured at 13.1 ± 0.9, 9.1 ± 1.2, and 7.1 ± 1.9 on 1 h, 24 h, and 48 h after injection, respectively. The SUVmax of HER2-positive tumors was relatively higher than HER2-negative tumors (8.6 ± 5.1 and 5.2 ± 2.8 on 48 h after injection, respectively). Tumor-to-background ratios were higher in the HER2-positive tumors than in the HER2-negative tumors. No adverse events related to 64Cu-NOTA-Trastuzumab were reported. The calculated effective dose with a 296 MBq injection of 64Cu-NOTA-Trastuzumab was 2.96 mSv. The highest absorbed dose was observed in the liver (0.076 mGy/MBq), followed by the spleen (0.063 mGy/MBq), kidney (0.044 mGy/MBq), and heart wall (0.044 mGy/MBq). CONCLUSIONS:64Cu-NOTA-Trastuzumab showed a specific uptake at the HER2-expressing tumors, thus making it a feasible and safe monitoring tool of HER2tumor status in patients with breast cancer. TRIAL REGISTRATION: CRIS, KCT0002790. Registered 02 February 2018, https://cris.nih.go.kr.
Entities:
Keywords:
64Cu-NOTA-Trastuzumab; Breast cancer; Computed tomography; HER-2; Positron emission tomography
Authors: Jason L J Dearling; Stephan D Voss; Patricia Dunning; Erin Snay; Frederic Fahey; Suzanne V Smith; James S Huston; Claude F Meares; S Ted Treves; Alan B Packard Journal: Nucl Med Biol Date: 2010-10-27 Impact factor: 2.408
Authors: Joanne E Mortimer; James R Bading; David M Colcher; Peter S Conti; Paul H Frankel; Mary I Carroll; Shan Tong; Erasmus Poku; Joshua K Miles; John E Shively; Andrew A Raubitschek Journal: J Nucl Med Date: 2013-12-12 Impact factor: 10.057
Authors: Nehmat Houssami; Petra Macaskill; Rosemary L Balleine; Michael Bilous; Mark D Pegram Journal: Breast Cancer Res Treat Date: 2011-06-23 Impact factor: 4.872
Authors: Ravindra A De Silva; Sandeep Jain; Kimberly A Lears; Hyun-Soon Chong; Chi Soo Kang; Xiang Sun; Buck E Rogers Journal: Nucl Med Biol Date: 2012-06-27 Impact factor: 2.408
Authors: Sietske B M Gaykema; Johan R de Jong; Patrick J Perik; Adrienne H Brouwers; Carolien P Schröder; Thijs H Oude Munnink; Alphons H H Bongaerts; Elisabeth G E de Vries; Marjolijn N Lub-de Hooge Journal: Mol Imaging Date: 2014 Impact factor: 4.488
Authors: Patrick J Madden; Muhammad S Arif; Mark E Becker; Michael D McRaven; Ann M Carias; Ramon Lorenzo-Redondo; Sixia Xiao; Cecily C Midkiff; Robert V Blair; Elizabeth Lake Potter; Laura Martin-Sancho; Alan Dodson; Elena Martinelli; John-Paul M Todd; Francois J Villinger; Sumit K Chanda; Pyone Pyone Aye; Chad J Roy; Mario Roederer; Mark G Lewis; Ronald S Veazey; Thomas J Hope Journal: Front Immunol Date: 2021-12-24 Impact factor: 7.561